Hematologist Optimistic about New Drugs for AML Including SMO and BCL-2 Inhibitors as Well as FLT3 Inhibitors

July 11, 2018
A leukemia specialist expressed in an interview with Jiho optimism not only about FLT3 inhibitors, which a number of drug makers are competing to develop, but about drugs with other mechanisms of action as well including smoothened (SMO) and B-cell...read more